Toll-like receptors (TLRs) are vital components of the immune system, acting as sentinels that detect and respond to ...

The FDA has approved a first-of-its-kind treatment for dry age-related macular degeneration (AMD), a leading cause of blindness in adults over 55.

Macular degeneration is a leading cause of vision loss, especially in people over the age of 50. It affects the macula, a ...

Since July 2024, faricimab has also been approved in Europe for the treatment of visual impairment due to macular edema ...

Astellas Pharma Inc. (ALPMY, ALPMY) announced that the U.S. Food and Drug Administration accepted the revised supplemental New Drug ...

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet ...

A specialty pharmacy company agreed to a $1.67 million settlement that it gave inventory management systems to retina ...

Researchers have developed a highly efficient gene editing therapy that could potentially treat Stargardt disease, the most common form of ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration, which causes blurred or reduced ... and ...

Fresenius, through its operating company Fresenius Kabi, is broadening its growing biopharma portfolio through a new licensing agreement with South Korea’s SamChunDang Pharm. Under the agreement, ...

Shares of Outlook Therapeutics jumped after the company said it continues to progress the development of its treatment for wet age-related macular degeneration ... said. New data from a current ...